Shandong Xinhua Pharmaceutical Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	no data
CEO ownership	n/a
Management average tenure	1.7yrs
Board average tenure	2.5yrs

Recent management updates

Recent updates

CEO

Shandong Xinhua Pharmaceutical has no CEO, or we have no data on them.

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Tongqing He	Chairman & Deputy GM	3.4yrs	CN¥1.61m	0.043% CN¥ 486.2k
Ning Hou	CFO, Financial Controller & Executive Director	no data	CN¥1.28m	0.048% CN¥ 547.6k
Changsheng Wei	Deputy GM & Manager of Administrative Personnel Department	no data	CN¥1.41m	0.020% CN¥ 221.9k
Wenhui Xu	Executive Director	1.6yrs	CN¥1.52m	0.035% CN¥ 403.0k
Xuesong Liu	Deputy General Manager	1.7yrs	CN¥831.80k	0.0034% CN¥ 38.5k
Changqiu Cao	Company Secretary	15.4yrs	CN¥446.80k	0.020% CN¥ 221.9k
Zuxing Kou	Deputy General Manager	no data	CN¥1.10m	0.0034% CN¥ 38.5k
Haifeng Guo	Head of Accounting Department	no data	no data	no data
Xiaohong He	Chief of Finance Department	no data	no data	no data

1.7yrs

Average Tenure

50.5yo

Average Age

Experienced Management: XIN's management team is not considered experienced ( 1.7 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Tongqing He	Chairman & Deputy GM	3.4yrs	CN¥1.61m	0.043% CN¥ 486.2k
Ning Hou	CFO, Financial Controller & Executive Director	1.6yrs	CN¥1.28m	0.048% CN¥ 547.6k
Wenhui Xu	Executive Director	1.6yrs	CN¥1.52m	0.035% CN¥ 403.0k
Zhichao Tao	Independent Supervisor	21.9yrs	CN¥20.00k	no data
Lie Xu	Non-Executive Director	13.9yrs	CN¥1.41m	0.043% CN¥ 486.2k
Guangcheng Pan	Independent Non-Executive Director	3.4yrs	CN¥100.00k	no data
Chengtong Liu	Chairman of Supervisory Committee	3.4yrs	no data	no data
Jianwei Zhu	Independent Non-Executive Director	3.4yrs	CN¥100.00k	no data
Peixue Ling	Non-Executive Director	1.6yrs	CN¥58.33k	no data
Chengyong Zhang	Non-Independent Director	less than a year	no data	no data
Jingjing Zhang	Non-Executive Director	less than a year	no data	no data
Ching Ching Cheung	Independent Non-Executive Director	less than a year	no data	no data

2.5yrs

Average Tenure

53yo

Average Age

Experienced Board: XIN's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Shandong Xinhua Pharmaceutical Management

Management criteria checks 0/4

Key information

Recent management updates

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments

Recent updates

First quarter 2024 earnings released: EPS: CN¥0.21 (vs CN¥0.23 in 1Q 2023)

Shandong Xinhua Pharmaceutical Company Limited to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings released: EPS: CN¥0.74 (vs CN¥0.62 in FY 2022)

Shandong Xinhua Pharmaceutical Company Limited Proposes Final Dividend for the Year Ended 31 December 2023

Shandong Xinhua Pharmaceutical Company Limited Receives Notification of Approval of Application for Marketing of Active Pharmaceutical Ingredient

Now 21% overvalued

Shandong Xinhua Pharmaceutical Company Limited Announces on Memantine Hydrochloride Tablets Obtaining the Drug Registration Certificate

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2023 Results on Mar 29, 2024

Shandong Xinhua Pharmaceutical Company Limited Announces Executive Changes

Shandong Xinhua Pharmaceutical Company Limited Receives Drug Registration Certificate of levamlodiping besylate tablets (2.5mg)

Third quarter 2023 earnings released: EPS: CN¥0.18 (vs CN¥0.15 in 3Q 2022)

Shandong Xinhua Pharmaceutical Company Limited Announces Approval of Marketing Application for Chemical Raw Material Drugs for Drugsof Febuxostat

Shandong Xinhua Pharmaceutical Company Limited Receives the Drug Registration Certificate of Alogliptin Benzoate Tablets Approved and Issued by the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Ling Peixue as Independent Non-Executive Director and Member of Strategic Development Committee and Remuneration and Examination Committee

Shandong Xinhua Pharmaceutical Company Limited Announces Final Dividend on A Shares for the Year 2022, Payable on July 26, 2023

Shandong Xinhua Pharmaceutical Company Limited Announces Rabeprazole Sodium Enteric-coated Tablets (20mg) Passing the GenericsConsistency Evaluation

Shandong Xinhua Pharmaceutical Company Limited Announces on New Drug Specifications and Passing the Generics Consistency Evaluation

Upcoming dividend of HK$0.22 per share at 3.7% yield

Shandong Xinhua Pharmaceutical Company Limited Obtains Alogliptin Benzoate Approval of Marketing Application for Chemical Raw Material Drugs

Shandong Xinhua Pharmaceutical Company Limited Receives Notice of Approval of Supplementary Drug Application from the National Medical Products Administration

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 26, 2023

Full year 2022 earnings released: EPS: CN¥0.62 (vs CN¥0.56 in FY 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Approves Board Appointments

Third quarter 2022 earnings released: EPS: CN¥0.15 (vs CN¥0.14 in 3Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report Q3, 2022 Results on Oct 25, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces Board Changes

Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.16 in 2Q 2021)

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2022 Results on Aug 30, 2022

Shandong Xinhua Pharmaceutical Company Limited Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 05 August 2022

Upcoming dividend of HK$0.18 per share

Shandong Xinhua Pharmaceutical Company Limited Announces Resignation of Du Deping as Executive Director and General Manager

Shandong Xinhua Pharmaceutical Company Limited Approves Final Dividend for the Year Ended 31 December 2021, Payable on 5 August 2022

Shandong Xinhua Pharmaceutical Company Limited, Annual General Meeting, Jun 30, 2022

Less than half of directors are independent

Shandong Xinhua Pharmaceutical Company Limited Proposes to Omit Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥0.56 (vs CN¥0.52 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.12 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.16 (vs CN¥0.14 in 2Q 2020)

Shandong Xinhua Pharmaceutical Company Limited announced that it expects to receive CNY 249.999998 million in funding from Hualu Investment Development Co., Ltd.

Full year 2020 earnings released: EPS CN¥0.52 (vs CN¥0.48 in FY 2019)

Shandong Xinhua Pharmaceutical Company Limited to Report Fiscal Year 2020 Results on Mar 31, 2021

New 90-day high: €0.60

New 90-day high: €0.47

Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments

New 90-day low: €0.38

Shandong Xinhua Pharmaceutical Company Limited Announces Board Appointments

Shandong Xinhua Pharmaceutical Company Limited Announces the Retirement of Certain Directors and Supervisors

Third quarter earnings released

Third quarter earnings released

Shandong Xinhua Pharmaceutical Company Limited to Report Nine Months, 2020 Results on Oct 22, 2020

New 90-day low: €0.38

New 90-day low - €0.41

New 90-day low - €0.44

Earnings released

Shandong Xinhua Pharmaceutical Company Limited to Report First Half, 2020 Results on Aug 24, 2020

Shandong Xinhua Pharmaceutical Company Limited (SEHK:719) completed the acquisition of 33% stake in Shandong Xinhua Wanbo Chemical Industrial Co., Ltd from Hualu Holding Co., Ltd.

CEO

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age